{'fraction_non_alphanumeric': 0.02199223803363519, 'fraction_numerical': 0.01034928848641656, 'mean_word_length': 5.910714285714286, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Update on utilities and cost–utility analyses

Purpose of review The purpose of this review is to summarize the recent and noteworthy utility studies and cost–utility analyses in the area of retina/vitreous during the period January 2004 to January 2006. Recent findings This review considers the cost-effectiveness of treatments for wet age-related macular degeneration, dry age-related macular degeneration, telemedicine in diabetic retinopathy, and utilities and patients with age-related macular degeneration and diabetic retinopathy. Summary Utilities are being used increasingly to measure health-related quality of life. Cost–utility analyses are becoming more readily available for comparing the incremental cost-effectiveness of different ophthalmic interventions.